GSK
About: In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Employees: 68,629
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
66% more call options, than puts
Call options by funds: $243M | Put options by funds: $146M
38% more first-time investments, than exits
New positions opened: 90 | Existing positions closed: 65
22% more capital invested
Capital invested by funds: $11.6B [Q4 2024] → $14.2B (+$2.6B) [Q1 2025]
18% more repeat investments, than reductions
Existing positions increased: 322 | Existing positions reduced: 273
17% more funds holding in top 10
Funds holding in top 10: 12 [Q4 2024] → 14 (+2) [Q1 2025]
0.62% more ownership
Funds ownership: 8.24% [Q4 2024] → 8.86% (+0.62%) [Q1 2025]
0% more funds holding
Funds holding: 833 [Q4 2024] → 837 (+4) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for GSK.
Financial journalist opinion
Based on 23 articles about GSK published over the past 30 days
Positive
Proactive Investors
1 day ago
GSK seeks broader European approval for RSV vaccine
GSK PLC (LSE:GSK, NYSE:GSK) has taken a step towards widening access to its respiratory syncytial virus (RSV) vaccine in Europe, with the European Medicines Agency accepting its application to expand the vaccine's use to all adults aged 18 and over. The vaccine, sold under the name Arexvy, is already authorised across Europe for adults aged 60 and over, as well as those aged 50 to 59 who are at increased risk due to underlying health conditions.
Positive
Reuters
2 days ago
GSK says EU heath regulator reviewing expansion of RSV vaccine
GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to include adults from 18 years of age.
Negative
Investors Business Daily
5 days ago
Vaccine Stocks Moderna, Pfizer Hit After A Surprise Blow From RFK Jr.
Vaccines stocks slipped late Monday after HHS fired all members of a CDC committee in charge of making vaccine suggestions.
Positive
Benzinga
5 days ago
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Positive
Zacks Investment Research
1 week ago
Here's Why GSK (GSK) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Positive
Zacks Investment Research
1 week ago
FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch
GSK's NDA for linerixibat, for treating itch in PBC patients, gets FDA review with a decision due in March 2026.
Negative
24/7 Wall Street
1 week ago
Dow Jones Industrial Average (DIA) Live June 3: OECD Cuts US GDP Forecast, DIA Dives
The OECD lowered US GDP forecasts for 2025 and 2026 today. Meta and Constellation are teaming up in a nuclear power supply agreement that will last 20 years.
Neutral
PRNewsWire
1 week ago
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 and 2026, requiring minimal to no growth over 2024 actuals to be achieved $225 million from royalty transaction announced today, in addition to the $1.1 billion upfront received in 2022 , and up to $200 million in milestones (of which $50 million was received in 2025), brings total potential lifetime value from Trelegy Ellipta monetization efforts to $1.525 billion First outcome from Strategic Review Committee's ongoing efforts to maximize shareholder value ; Board remains committed to returning excess capital to shareholders DUBLIN , June 2, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that it has entered into a definitive agreement to sell its remaining royalty interest in net sales of Trelegy Ellipta ("Trelegy") to GSK (NYSE: GSK) for $225 million in cash. "Through this agreement with GSK to monetize our outer-year Trelegy royalties, we are translating our long-standing confidence in Trelegy's sustained success into immediate value for Theravance Biopharma shareholders," said Rick E Winningham, CEO of Theravance Biopharma.
Positive
Zacks Investment Research
2 weeks ago
Glaxo (GSK) Up 3.2% Since Last Earnings Report: Can It Continue?
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock?
Neutral
CNBC Television
2 weeks ago
Carat Group's Fred Hassan dives into what pharma companies to watch at 2025 ASCO Annual Meeting
Fred Hassan, Carat Group chairman, joins 'Money Movers' to discuss pharma innovation in 2025 and what companies he's watching in the sector.
Charts implemented using Lightweight Charts™